**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**
**宜昌東陽光長江藥業股份有限公司**
*(A joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock Code: 01558)**

# VOLUNTARY ANNOUNCEMENT
# APPLICATION FOR LAUNCHING YIQIBUVIR TABLETS ACCEPTED

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors (the "**Board**") of the Company is pleased to announce that the Company's self-researched and developed product, Yiqibuvir Tablets (0.3g) (the "**Product**"), has received the Notice of Acceptance issued by the National Medical Products Administration of the People's Republic of China, and the new drug application of the Product has been accepted. The acceptance number is CXHS2300069.

The Product is a Class 1 innovative drug in China, which is a NS5B PARP inhibitor of Pan-genotypic chronic Hepatitis C treatment direct antiviral agent (DAA). In combination with Antaitasvir Capsules, the Product is used for the treatment of HCV infection in adults with genotypes 1, 2, 3, and 6 in primary or interferon-treated cases, which may or may not be comorbid with compensated cirrhosis. The Product has the advantages of high cure rate, high safety and not prone to develop drug resistance.

Hepatitis C Virus (Hepatitis C/HCV) is one of the key components of the antiviral market. It is currently estimated that there are approximately 10 million chronic HCV infected patients in the People's Republic of China (the "**PRC**"), while approximately 70% of which have not been identified. The World Health Organization (WHO) proposes to eliminate viral hepatitis as a public health hazard, reduce the infection rate of new viral hepatitis by 90% and the mortality rate by 65%, as well as to respectively achieve the diagnosis rate of 90% and treatment rate of 80% by 2030. In 2021, the Nine Ministries of the State, including the Health Commission, jointly released the "Work Program for Eliminating Hepatitis C Public Health Hazardous Action (2021–2030)《消除丙型肝炎公共衛生危害行動工作方案(2021–2030年)》", with an aim to achieve an antiviral treatment rate of more than 80% for chronic Hepatitis C patients who are eligible for treatment by 2030. Therefore, the next ten years will be a crucial decade for the national elimination of Hepatitis C, to which the Company will make an important contribution.

This new drug be applied for launching is mainly based on the Phase II/III clinical trial of the Product in combination with Antaitasvir Capsules, and the data statistics showed that the major therapeutic endpoints were reached, which was statistically significant, and the 12-week sustained virological response rate (SVR12) reached 95%. Safety statistics showed that the overall safety profile was favorable and manageable.

The Company has a comprehensive plan in the field of anti-Hepatitis C drugs. Reference is made to the announcement of the Company dated 28 December 2020 in relation to the approval for launch of the Company's product, Emitasvir Phosphate Capsules. The Company has currently started the marketing of the relevant type of product. Looking forward, if the application for approval of the launching of Yiqibuvir Tablets is granted by the National Medical Products Administration, the Company's product portfolio in the field of antiviral drugs will be further enriched and enhance the Company's capability to provide patients with more affordable and quality drugs choices.

This announcement is a voluntary announcement made by the Company for the purpose of informing investors of the latest business development of the Group, and does not contain any advertisement or intention to encourage usage of any drug, surgical device, treatment or oral product.

On behalf of the Board
**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**
**TANG Xinfa**
*Chairman*

Hubei, the People's Republic of China
15 August 2023

*As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive Directors; Mr. TANG Xinfa as a non-executive Director; and Mr. TANG Jianxin, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.*